Intractable Rare Dis Res. 2021;10(2):122-125. (DOI: 10.5582/irdr.2020.03144)

Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Gupta S, Rakhra A, Thallapally V, Nahas J


Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.

KEYWORDS: anti-HMGCR, immune-mediated necrotizing myopathy, immunosuppressants, rituximab

Full Text: